Aschengrau Ann, Mussi-Pinhata Marisa M, Moye John, Chakhtoura Nahida, Patel Kunjal, Williams Paige L, Karalius Brad, Garvie Patricia A, Monte Dina, Whalen Frances, Lebov Jill, Seage George R
Department of Epidemiology, Boston University School of Public Health, Boston, MA, United States.
Department of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Front Glob Womens Health. 2021 Jul 2;2:574327. doi: 10.3389/fgwh.2021.574327. eCollection 2021.
Zika virus (ZIKV) infection may adversely affect pregnancies of women living with HIV (WLHIV). Because no study to date has focused on maternal and child effects of HIV and ZIKV co-infection in pregnant women, we undertook the International Prospective Cohort Study of HIV and Zika in Infants and Pregnancy (HIV ZIP). The aims of this two-phase study of pregnant women and their infants are to compare the incidence of ZIKV infection among pregnant women with and without HIV infection and to determine the risk of adverse maternal and child outcomes associated with ZIKV/HIV co-infection at clinical sites in Brazil, Puerto Rico, and the continental United States. Phase I was designed to enroll pregnant women/infant pairs who were: (1) infected with HIV only, (2) infected with ZIKV only, (3) infected with HIV and ZIKV, and (4) not infected with either HIV or ZIKV. A key goal of this phase was to assess the feasibility of enrolling 200 women/infant pairs within a year, with a target of 150 WLHIV, 50 HIV-uninfected women, and a minimum of 20 who were co-infected with HIV and ZIKV. If the feasibility of Phase I proved successful, Phase II would enroll up to 1,800 additional pregnant women/infant pairs to the same four groups. Enrolled women in both phases were to be followed throughout their pregnancy and up to 6 weeks post-partum. Infants were also to be followed for 1 year after birth. To date, Phase 1 data collection and follow-up have been completed. Delineation of possible harmful effects of HIV/ZIKV co-infection will allow the formulation of standard-of-care recommendations to minimize adverse effects but enable the continuation of preventive HIV therapy. Furthermore, while the prospective HIV ZIP study was developed before the COVID pandemic, it is especially relevant today since it can be easily adapted to provide critically important information on the impact of COVID-19 infection or other still unrecognized new agents among pregnant women and their offspring worldwide.
寨卡病毒(ZIKV)感染可能会对感染艾滋病毒的孕妇(WLHIV)的妊娠产生不利影响。由于迄今为止尚无研究关注孕妇中艾滋病毒与寨卡病毒合并感染对母婴的影响,我们开展了“婴儿与孕期艾滋病毒和寨卡病毒国际前瞻性队列研究”(HIV ZIP)。这项针对孕妇及其婴儿的两阶段研究的目的是比较感染艾滋病毒和未感染艾滋病毒的孕妇中寨卡病毒感染的发生率,并确定在巴西、波多黎各和美国大陆的临床地点,与寨卡病毒/艾滋病毒合并感染相关的母婴不良结局风险。第一阶段旨在招募符合以下条件的孕妇/婴儿对:(1)仅感染艾滋病毒;(2)仅感染寨卡病毒;(3)同时感染艾滋病毒和寨卡病毒;(4)既未感染艾滋病毒也未感染寨卡病毒。该阶段的一个关键目标是评估在一年内招募200对妇女/婴儿对的可行性,目标是150对感染艾滋病毒的孕妇、50对未感染艾滋病毒的妇女,以及至少20对同时感染艾滋病毒和寨卡病毒的孕妇。如果第一阶段证明可行,第二阶段将再招募多达1800对孕妇/婴儿对,分为相同的四组。两个阶段招募的妇女在整个孕期及产后6周都要接受随访。婴儿在出生后也要随访1年。迄今为止,第一阶段的数据收集和随访已经完成。明确艾滋病毒/寨卡病毒合并感染可能的有害影响,将有助于制定护理标准建议,以尽量减少不良影响,但同时能够继续进行预防性艾滋病毒治疗。此外,虽然前瞻性HIV ZIP研究是在新冠疫情之前开展的,但在今天它尤其具有相关性,因为它可以很容易地进行调整,以提供关于新冠病毒感染或其他尚未被认识的新病原体对全球孕妇及其后代影响的极其重要的信息。